Linde India: The Supreme Court rejected Linde India's appeal against a Securities and Exchange Board of India (SEBI) ...

Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of ...

AstraZeneca Pharma India has received approval from the CDSO for the import, sale, and distribution of Durvalumab.

Benchmark equity indices closed flat on Tuesday after hitting record highs. Nifty50 surpassed 26,000 and Sensex crossed ...

Astrazeneca Pharma India has received CDSO's (Central Drugs Standard Control Organisation) nod for the import of Durvalumab ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 ...

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India.

The stock jumped more than 12% to hit its lifetime high of Rs 7,598. The surge was as the company received Central Drugs ...

By Manvi Pant BENGALURU (Reuters) -Indian shares reached new record highs for the fourth consecutive session on Tuesday, driven by last week's U.S. interest rate cut and supported by gains in domestic ...

This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control ...